Aktiesnakken — Juli 2010
-
altså om de når at få nye stoffer langt nok frem til at overtage fra Cipralex
-
Hvis de klare skærene så er den utrolig billig på dette niveau
-
Jeg synes generelt ders nye CEO gør det utrolig godt. Men de er ikke i mål endnu(hvilket kursen også afspejler)
-
Som jeg ser det så SKAL der nye opkøb til
-
Turban det afhænger selvføgelig af hvad de køber og hvad prisen er for det.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind